1. Isolation and Characterization of CD276+/HLA-E+ Human Subendocardial Mesenchymal Stem Cells from Chronic Heart Failure Patients: Analysis of Differentiative Potential and Immunomodulatory Markers Expression
- Author
-
Rita Anzalone, Melania Lo Iacono, Francesco Cappello, Giovanni Zummo, Pantaleo Giannuzzi, Tiziana Corsello, Tiziana Loria, Giampiero La Rocca, Simona Corrao, Felicia Farina, Antonino Di Stefano, Anzalone, R, Corrao, S, Lo Iacono, M, Loria, T, Corsello, T, Cappello, F, Di Stefano, A, Giannuzzi, P, Zummo, G, Farina, F, and La Rocca, G
- Subjects
Pathology ,medicine.medical_specialty ,B7 Antigens ,Heart Ventricles ,Gene Expression ,Cell Separation ,Biology ,Cell therapy ,HLA-E ,Antigens, CD ,Osteogenesis ,Cellular cardiomyoplasty ,medicine ,Humans ,Immunologic Factors ,Myocardial infarction ,Cells, Cultured ,Heart Failure ,Adipogenesis ,Mesenchymal stem cells, human heart stromal progenitors, post-infarct chronic heart failure, cardiomyocyte markers, immune modulation, inflammation, cardiac remodelling, regenerative medicine ,Settore BIO/16 - Anatomia Umana ,Histocompatibility Antigens Class I ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,Cell Biology ,Hematology ,Anatomy ,medicine.disease ,Clinical trial ,medicine.anatomical_structure ,Ventricle ,Heart failure ,Chondrogenesis ,Biomarkers ,Developmental Biology - Abstract
Mesenchymal stem cells (MSCs) are virtually present in all postnatal organs as well as in perinatal tissues. MSCs can be differentiated toward several mature cytotypes and interestingly hold potentially relevant immunomodulatory features. Myocardial infarction results in severe tissue damage, cardiomyocyte loss, and eventually heart failure. Cellular cardiomyoplasty represents a promising approach for myocardial repair. Clinical trials using MSCs are underway for a number of heart diseases, even if their outcomes are hampered by low long-term improvements and the possible presence of complications related to cellular therapy administration. Therefore, elucidating the presence and role of MSCs that reside in the post-infarct human heart should provide essential alternatives for therapy. In the current article we show a novel method to reproducibly isolate and culture MSCs from the subendocardial zone of human left ventricle from patients undergoing heart transplant for post-infarct chronic heart failure (HSE-MSCs, human subendocardial mesenchymal stem cells). By using both immunocytochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR), we demonstrated that these cells do express key MSCs markers and do express heart-specific transcription factors in their undifferentiated state, while lacking strictly cardiomyocyte-specific proteins. Moreover, these cells do express immunomodulatory molecules that should disclose their further potential in immune modulation processes in the post-infarct microenvironment. Another novel datum of potentially relevant interest is the expression of cardiac myosin heavy chain at nucclear level in HSE-MSCs. Standard MSCs trilineage differentiation experiments were also performed. The present paper adds new data on the basic biological features of heart-resident MSCs that populate the organ following myocardial infarction. The use of heart-derived MSCs to promote in-organ repair or as a cellular source for cardiomyoplasty is a fascinating and challenging task, which deserves further research efforts.
- Published
- 2013
- Full Text
- View/download PDF